Molecular Pathway Activation Markers Are Associated with Efficacy of Trastuzumab Therapy in Metastatic HER2-Positive Breast Cancer Better than...
Sorokin M. I., Ignatev K., Barbara V., Vladimirova U., Muraveva A., Suntsova M. V., Gaifullin N., Vorotnikov I., Kamashev D. E`., Bondarenko A., Baranova M., Poddubskaya E. V., Buzdin A. A.
Biochemistry (Moscow)
Vol.85, Issue7, P. 758-772
Опубликовано: 2020
Тип ресурса: Статья
DOI:10.1134/S0006297920070044
Аннотация:
Abstract: Increased expression or amplification of HER2 receptor tyrosine kinase gene ERBB2 is well-known and widely used as a prognostic biomarker of breast cancer (BC) response to the targeted treatment with trastuzumab and its analogs. Considering that part of the BC patients overexpressing HER2 does not respond to trastuzumab, clinical trial NCT03521245 was initiated to identify additional gene expression and molecular pathway activation response biomarkers to trastuzumab treatment in HER2-positive BC. Using RNA sequencing gene expression in 23 formalin-fixed, paraffin embedded HER2 positive BC tissue blocks from patients who either responded or not responded to trastuzumab treatment was profiled. Differentially regulated genes and molecular pathways were identified in the groups of trastuzumab responders and non-responders. These results were next compared with the 42 previously published BC trastuzumab responder and non-responder RNA sequencing profiles from the clinical trials N
Ключевые слова:
breast cancer; ERBB2; HER2; NCT03521245; personalized medicine; RNA sequencing; targeted therapy; transcriptomics; trastuzumab
Язык текста: Английский
ISSN: 1608-3040
Sorokin M. I. Maksim Igorevich 1989-
Ignatev K.
Barbara V.
Vladimirova U.
Muraveva A.
Suntsova M. V. Mariya Vladimirovna 1986-
Gaifullin N.
Vorotnikov I.
Kamashev D. E`. Dmitrij E`duardovich 1964-
Bondarenko A.
Baranova M.
Poddubskaya E. V. Elena Vladimirovna 1965-
Buzdin A. A. Anton Aleksandrovich 1977-
Сорокин М. И. Максим Игоревич 1989-
Игнатев К.
Барбара В.
Владимирова У.
Муравева А.
Сунцова М. В. Мария Владимировна 1986-
Гаифуллин Н.
Воротников И.
Камашев Д. Э. Дмитрий Эдуардович 1964-
Бондаренко А.
Баранова М.
Поддубская Е. В. Елена Владимировна 1965-
Буздин А. А. Антон Александрович 1977-
Molecular Pathway Activation Markers Are Associated with Efficacy of Trastuzumab Therapy in Metastatic HER2-Positive Breast Cancer Better than Individual Gene Expression Levels
Molecular Pathway Activation Markers Are Associated with Efficacy of Trastuzumab Therapy in Metastatic HER2-Positive Breast Cancer Better than...
Текст визуальный непосредственный
Biochemistry (Moscow)
Pleiades Publishing, Ltd.
Vol.85, Issue7 P. 758-772
2020
Статья
breast cancer ERBB2 HER2 NCT03521245 personalized medicine RNA sequencing targeted therapy transcriptomics trastuzumab
Abstract: Increased expression or amplification of HER2 receptor tyrosine kinase gene ERBB2 is well-known and widely used as a prognostic biomarker of breast cancer (BC) response to the targeted treatment with trastuzumab and its analogs. Considering that part of the BC patients overexpressing HER2 does not respond to trastuzumab, clinical trial NCT03521245 was initiated to identify additional gene expression and molecular pathway activation response biomarkers to trastuzumab treatment in HER2-positive BC. Using RNA sequencing gene expression in 23 formalin-fixed, paraffin embedded HER2 positive BC tissue blocks from patients who either responded or not responded to trastuzumab treatment was profiled. Differentially regulated genes and molecular pathways were identified in the groups of trastuzumab responders and non-responders. These results were next compared with the 42 previously published BC trastuzumab responder and non-responder RNA sequencing profiles from the clinical trials N